Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,158 | 694 | 121 | 70 | 13 |
| TOTAL | $1,887 | $1,797 | $1,594 | $106 | $76 |
| Non-Current Assets | |||||
| PPE Net | 79 | 88 | 103 | 117 | 137 |
| Other Non-Current Assets | 47 | 47 | 47 | 47 | 47 |
| TOTAL | $126 | $135 | $150 | $164 | $184 |
| Total Assets | $2,012 | $1,933 | $1,744 | $270 | $259 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 8,304 | 4,882 |
| Accounts payable and accrued liabilities | 1,098 | 1,110 | 1,550 | 2,251 | 2,415 |
| Accrued Expenses | 929 | 1,131 | 1,382 | 1,207 | 1,193 |
| TOTAL | $2,102 | $2,349 | $3,279 | $17,388 | $10,764 |
| Non-Current Liabilities | |||||
| Long Term Debt | 29 | 31 | 1,039 | 36 | 3,254 |
| Other Non-Current Liabilities | 1,416 | 805 | 213 | 3,305 | 3,936 |
| TOTAL | $1,509 | $909 | $1,331 | $3,424 | $7,279 |
| Total Liabilities | $3,611 | $3,257 | $4,610 | $20,813 | $18,043 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 76 | 58 | 53 | 53 | 49 |
| Common Shares | 2 | 2 | 2 | 2 | 1 |
| Retained earnings | -123,242 | -121,095 | -114,047 | -84,523 | -78,301 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $-1,598 | $-1,325 | $-2,866 | $-20,543 | $-17,783 |
| Total Liabilities And Equity | $2,012 | $1,933 | $1,744 | $270 | $259 |